NCT06172205招募中3 期
Infusional FOLFOX Plus Camrelizumab and Apatinib Versus HAIC-FOLFOX Plus Camrelizumab and Apatinib for Hepatocellular Carcinoma of BCLC C Stage: A Multi-center Randomized Phase III Trial
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University1 个研究点 分布在 1 个国家目标入组 262 人开始时间: 2023年7月1日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 入组人数
- 262
- 试验地点
- 1
- 主要终点
- 6-mon PFSR
研究概览
简要总结
This is a multi-center randomized phase III clinical study of first-line intravenous FOLFOX plus Camrelizumab and apatinib versus HAIC-FOLFOX plus Camrelizumab and apatinib for BCLC C stage hepatocellular carcinoma.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age 18-75, male or female;
- •The clinical diagnosis conforms to primary hepatocellular carcinoma (HCC) and the lesion conforms to BCLC stage C.
- •Child-pugh liver function grading: Grade A or B
- •Did not received any type of other first-line drugs such as Sorafenib
- •According to RECIST 1.1 standard, patients have at least one measurable lesion (CT/MRI scan long diameter ≥10mm or CT/MRI scan short diameter ≥15mm for lymph node lesions, and the lesion has not received radiotherapy, freezing or other local treatments);
- •ECOG PS score 0-2;
- •Expected survival ≥ 12 weeks;
- •The function of vital organs meets the following requirements (excluding the use of any blood component and cell growth factor within 14 days): Blood routine:White blood cells count ≥3.0×10^9/L Platelet count ≥70×10^9/L Hemoglobin ≥80g/L(without blood transfusion); Liver and kidney function: Serum creatinine (SCr) ≤ 1.5 times upper limit of normal value (ULN); Total bilirubin (TBIL) ≤ 3 times the upper limit of normal value (ULN); AST or ALT levels ≤ 3 times the upper limit of normal value (ULN)
- •Subjects with HBV or HCV infection should receive anti-virus treatment without interfron.
- •Women of childbearing age should agree to use contraceptives (such as intrauterine devices, contraceptives or condoms) during and within six months of the end of medication;Patients with negative serum or urine pregnancy tests within 7 days prior to study inclusion and who must be non-lactating, and males should agree to use contraceptives during the study period and for 6 months after the end of the study period.
- •Patients volunteered to participate in this study and signed informed consent; Subjects have good compliance and cooperate with the follow-up.
排除标准
- •Have received immunotherapeutic drugs or interferon in the past.
- •Severe allergic reaction to other monoclonal antibodies, immunotherapy or chemotherapy.
- •Female subjects with pregnancy or on feeding.
- •Patients with congenital or acquired immune deficiencies.
- •Abnormal coagulation function (INR>2.0, PT>16s), have bleeding tendency or are receiving thrombolysis or anticoagulation therapy, and allow preventive use of low-dose aspirin and low-molecular-weight heparin
- •The patient has suffered from other malignant tumors at the same time (except for cured skin basal cell carcinoma and cervical carcinoma in situ)
- •The patient has active infection, fever of unknown origin within 7 days (CTCAE>2)
- •Patients with congenital or acquired immune deficiencies.
- •Severe coagulation dysfunction (INR > 2.0, PT > 16s), with a significant tendency to bleed (including but not limited to vomiting blood or passing blood in stool daily within the past 3 months);
- •Moderate to severe ascites with clinical symptoms that require therapeutic puncture or drainage, or Child-Pugh score > 2 (except for cases where imaging shows only a small amount of ascites without clinical symptoms); uncontrolled or moderate to large pleural effusion or pericardial effusion;
- •Patients are to be excluded if they have a history of gastrointestinal bleeding within 6 months prior to the start of the study treatment, or have a definite tendency for gastrointestinal bleeding, including but not limited to: bleeding-risk or severe esophageal/gastric varices, locally active ulcerative lesions, or persistently positive fecal occult blood tests.
- •Occurrence of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to the start of study treatment;
- •Occurrence of thrombotic or embolic events within 6 months prior to the start of study treatment, such as cerebrovascular accidents (including transient ischemic attack, cerebral hemorrhage, cerebral infarction, cerebrovascular abnormalities, cerebral aneurysm), pulmonary embolism, etc.;
- •Major vascular disease within 6 months prior to the start of study treatment (e.g., aortic aneurysm requiring surgical repair or recent peripheral arterial thrombosis); severe, unhealed, or dehisced wounds, as well as active ulcers or untreated fractures; Criteria for Discontinuation of Study Treatment
- •Previous or current presence of central nervous system metastases;
- •Individuals with a history of substance abuse of psychiatric medications who are unable to quit, or those with mental disorders; or those with brain metastases or hepatic encephalopathy;
- •According to the judgment of the investigator, the patients with factors that may affect the results of the study or cause the study to be terminated midway, such as alcoholism, drug abuse, other serious diseases (including mental illness) need to be treated together, severe laboratory abnormalities, accompanied by family or social factors, which will affect the safety of patients
研究组 & 干预措施
Infusional FOLFOX
Experimental
Infusional mFOLFOX7 plus Camrelizumab and apatinib
干预措施: intravenous FOLFOX7 plus Camrelizumab and apatinib (Drug)
HAIC-FOLFOX
Active Comparator
HAIC-FOLFOX plus Camrelizumab and apatinib
干预措施: HAIC-FOLFOX plus Camrelizumab and apatinib (Drug)
结局指标
主要结局
6-mon PFSR
时间窗: up to approximately 3 years
The incidence of disease progression within the first 6 months of the patient's treatment
Hepatic Reserve Function Impairment Rate(ICG-15min)
时间窗: up to approximately 3 years
ICG-R15 is a clinical parameter that assesses the volume of remaining functional hepatocytes, which reflects the functional reserve status of the liver. It is the most commonly used indicator for measuring the severity of liver damage.
次要结局
- mORR(up to approximately 3 years)
- ORR(up to approximately 3 years)
- DOR(up to approximately 3 years)
- DCR(up to approximately 3 years)
- 1y-PFSR(1 year)
- 2y-OSR(2 year)
- OS(up to approximately 5 years)
- TRAE(up to approximately 3 years)
- conversion rate(up to approximately 3 years)
- PFS(up to approximately 3 years)
- 9-mon PFSR(up to approximately 3 years)
- 18-mon OSR(2 years)
研究者
研究点 (1)
Loading locations...
相似试验
招募中
2 期
mFOLFOX7 Plus Camrelizumab and Apatinib for Advanced HCCStage III Hepatocellular Cancer (CNLC Staging)NCT05412589Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University35
进行中（未招募）
3 期
Study to Evaluate the Efficacy of FOLFOX + Panitumumab Followed by FOLFIRI + Bevacizumab (Sequence 1) Versus FOLFOX + Bevacizumab Followed by FOLFIRI + Panitumumab (Sequence 2) in Untreated Patients With Wild-type RAS Metastatic, Primary Left-sided, Unresectable Colorectal CancerColorectal CancerNCT03635021Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)419
已完成
3 期
Study of 5-Fluorouracil/Leucovorin/Oxaliplatin (FOLFOX) + Bevacizumab Versus 5-Fluorouracil/Leucovorin/Oxaliplatin/Irinotecan (FOLFOXIRI) + Bevacizumab as First Line Treatment of Patients With Metastatic Colorectal Cancer Not Previously Treated and With Three or More Circulating Tumoral CellsMetastatic Colorectal CancerNCT01640405Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)350
已完成
2 期
Randomized Phase II Study of FOLFOX Versus FOLFIRI.3 in Gemcitabine-refractory Pancreatic CancerMetastatic Pancreatic CancerNCT00786006Asan Medical Center61
招募中
3 期
Neoadjuvant FOLFOXIRI Versus CapeOX Chemotherapy for Local Advanced Rectal CancerRectal CancerNCT05201430Fudan University300